Clene to Present at the Jones Healthcare and Technology Innovation Conference
Clene (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company specializing in neurodegenerative disease treatments including ALS and MS, has announced its participation in the upcoming Jones Healthcare and Technology Innovation Conference.
The company's management will deliver a presentation on April 9, 2025, at 11:30 am PT at the Venetian Resort in Las Vegas, NV. The event will also feature one-on-one investor meetings, which can be arranged through Jones representatives.
Interested parties can access the presentation webcast through the 'Events' section of Clene's website or via online registration.
Clene (Nasdaq: CLNN), un'azienda biofarmaceutica in fase clinica avanzata specializzata nel trattamento delle malattie neurodegenerative, tra cui SLA e SM, ha annunciato la sua partecipazione alla prossima Jones Healthcare and Technology Innovation Conference.
La direzione dell'azienda presenterà un intervento il 9 aprile 2025, alle 11:30 ora PT presso il Venetian Resort a Las Vegas, NV. L'evento includerà anche incontri individuali con gli investitori, che possono essere organizzati tramite i rappresentanti di Jones.
Le parti interessate possono accedere alla trasmissione in diretta della presentazione attraverso la sezione 'Eventi' del sito web di Clene o tramite registrazione online.
Clene (Nasdaq: CLNN), una compañía biofarmacéutica en etapa clínica avanzada especializada en tratamientos para enfermedades neurodegenerativas, incluyendo ELA y EM, ha anunciado su participación en la próxima Jones Healthcare and Technology Innovation Conference.
La dirección de la compañía realizará una presentación el 9 de abril de 2025, a las 11:30 am PT en el Venetian Resort en Las Vegas, NV. El evento también contará con reuniones individuales con inversores, que pueden ser organizadas a través de representantes de Jones.
Las partes interesadas pueden acceder a la transmisión en vivo de la presentación a través de la sección 'Eventos' en el sitio web de Clene o mediante registro en línea.
Clene (Nasdaq: CLNN), 신경퇴행성 질환 치료를 전문으로 하는 후기 임상 단계의 생물 제약 회사로, ALS 및 MS를 포함한 질병 치료에 주력하고 있습니다. 이 회사는 다가오는 Jones Healthcare and Technology Innovation Conference에 참여한다고 발표했습니다.
회사의 경영진은 2025년 4월 9일, 오전 11:30 PT에 라스베이거스, NV의 Venetian Resort에서 발표를 진행할 예정입니다. 이 행사에서는 투자자들과의 일대일 미팅도 진행되며, 이는 Jones의 대표를 통해 조정할 수 있습니다.
관심 있는 분들은 Clene 웹사이트의 '이벤트' 섹션을 통해 발표 웹캐스트에 접근하거나 온라인 등록을 통해 참여할 수 있습니다.
Clene (Nasdaq: CLNN), une entreprise biopharmaceutique en phase clinique avancée spécialisée dans le traitement des maladies neurodégénératives, y compris ALS et SM, a annoncé sa participation à la prochaine Jones Healthcare and Technology Innovation Conference.
La direction de l'entreprise fera une présentation le 9 avril 2025, à 11h30 PT au Venetian Resort à Las Vegas, NV. L'événement comprendra également des réunions individuelles avec des investisseurs, qui peuvent être organisées par l'intermédiaire des représentants de Jones.
Les parties intéressées peuvent accéder à la diffusion en direct de la présentation via la section 'Événements' du site web de Clene ou par inscription en ligne.
Clene (Nasdaq: CLNN), ein biopharmazeutisches Unternehmen in der späten klinischen Phase, das sich auf die Behandlung neurodegenerativer Erkrankungen wie ALS und MS spezialisiert hat, hat seine Teilnahme an der bevorstehenden Jones Healthcare and Technology Innovation Conference bekannt gegeben.
Die Unternehmensleitung wird am 9. April 2025 um 11:30 Uhr PT im Venetian Resort in Las Vegas, NV, eine Präsentation halten. Die Veranstaltung wird auch Einzelgespräche mit Investoren umfassen, die über Vertreter von Jones organisiert werden können.
Interessierte Parteien können über den Bereich 'Veranstaltungen' auf der Website von Clene oder durch Online-Registrierung auf den Live-Stream der Präsentation zugreifen.
- None.
- None.
SALT LAKE CITY, April 01, 2025 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), today announced that management will present at the Jones Healthcare and Technology Innovation Conference and host 1x1 investor meetings.
Date: April 9, 2025
Time of Presentation: 11:30 am PT
Location: Las Vegas, NV, Venetian Resort
Format: Presentation
1x1 Meetings: Please contact your Jones representative.
A webcast of the presentation will be available on the “Events” section of the Clene website. Alternatively, one can register online to view the webcast here: link
About Clene
Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary, Clene Nanomedicine Inc., is a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis, Parkinson’s disease, and multiple sclerosis. CNM-Au8® is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene Nanomedicine, Inc. The company is based in Salt Lake City, Utah, with R&D and manufacturing operations in Maryland. For more information, please visit www.clene.com or follow us on X (formerly Twitter) and LinkedIn.
Contacts:
| Media Contact Ignacio Guerrero-Ros, Ph.D., or David Schull Russo Partners, LLC Ignacio.guerrero-ros@russopartnersllc.com David.schull@russopartnersllc.com (858) 717-2310 | Investor Contact Kevin Gardner LifeSci Advisors kgardner@lifesciadvisors.com 617-283-2856 |
FAQ
When and where is Clene (CLNN) presenting at the Jones Healthcare Conference 2025?
How can investors attend Clene's (CLNN) presentation at the Jones Conference?
What therapeutic areas does Clene (CLNN) focus on in their drug development?
What is Clene's (CLNN) current development stage as a biopharmaceutical company?
